Clemmesen J O, Tygstrup N, Ott P
Department of Hepatology, Rigshospitalet, University of Copenhagen, Denmark.
Hepatology. 1998 Mar;27(3):666-73. doi: 10.1002/hep.510270305.
The magnitude of hepatic plasma flow in patients with liver failure and hepatic encephalopathy (HE) is unknown because a reliable flow estimate has not been available. The purpose of this study was to estimate hepatic plasma flow in patients with HE and to evaluate indocyanine green (ICG) and sorbitol as test compounds. Fourteen patients with acute liver failure (ALF) and nine patients with chronic liver failure (CLF), all with HE grade II or more, were studied. After hepatic vein catheterization, hepatic plasma flow was estimated by use of constant infusion, simultaneous arterial and hepatic vein concentration measurements, and calculated according to Fick's principle. The hepatic extraction fraction of D-sorbitol 0.179+/-0.144 (mean+/-SD) was higher than the hepatic extraction fraction of ICG 0.054+/-0.085 (P < .001). The low hepatic extraction fraction of ICG rendered this compound unfit for estimation of hepatic plasma flow in these patients. In contrast, by using D-sorbitol the hepatic plasma flow could be estimated in 21 of 23 patients with a median SD of 8.4% (range, 2.6% to 29%). The D-sorbitol estimated hepatic plasma flow was 1.2+/-0.5 L/min (n = 12) in patients with ALF and 1.4+/-0.9 L/min (n = 9) in patients with CLF. These values are higher than what has been reported in normal subjects and in patients with cirrhosis without HE. An elevated hepatic flow should increase oxygen delivery and may enhance the failing liver's ability to remove substances from the blood. At the same time, hepatic first pass metabolism is reduced. We conclude that an elevated hepatic flow in these patients is of clinical importance.
由于尚未获得可靠的血流估计值,肝衰竭和肝性脑病(HE)患者的肝血浆流量大小尚不清楚。本研究的目的是估计HE患者的肝血浆流量,并评估吲哚菁绿(ICG)和山梨醇作为测试化合物。研究了14例急性肝衰竭(ALF)患者和9例慢性肝衰竭(CLF)患者,所有患者均为II级或更高级别的HE。在进行肝静脉插管后,通过持续输注、同时测量动脉和肝静脉浓度,并根据菲克原理计算来估计肝血浆流量。D-山梨醇的肝提取率为0.179±0.144(平均值±标准差),高于ICG的肝提取率0.054±0.085(P <.001)。ICG的低肝提取率使得该化合物不适用于估计这些患者的肝血浆流量。相比之下,使用D-山梨醇可在23例患者中的21例中估计肝血浆流量,中位数标准差为8.4%(范围为2.6%至29%)。ALF患者中D-山梨醇估计的肝血浆流量为1.2±0.5 L/分钟(n = 12),CLF患者中为1.4±0.9 L/分钟(n = 9)。这些值高于正常受试者和无HE的肝硬化患者的报道值。肝血流增加应会增加氧输送,并可能增强衰竭肝脏从血液中清除物质的能力。同时,肝首过代谢降低。我们得出结论,这些患者肝血流增加具有临床重要性。